Liste des Actualités Leucémie

lundi 21 janvier 2008 Ipsogen reports recommendation of JAK2V617F mutation screening in World Health Organization 2008 criteria and point-of-care diagnostic algorithms

Ipsogen SAS today reported that the 2008 revision of the WHO document on the classification of chronic myeloproliferative diseases (CMPDs) hasincorporated new information on the molecular pathogenesis of BCR–ABL negative...

Categorie: Leucémie

lundi 03 décembre 2007 Ipsogen to undertake pilot study on JAK2 cancer biomarker with AstraZeneca

IPSOGEN, a leading molecular diagnostic company based in France andConnecticut, USA today announced that it has entered into a pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research.Under...

Categorie: Leucémie

mercredi 28 novembre 2007 A multi-center evaluation of WT1 assay in AML patients presented at the 49th Annual Meeting of the American Society of Hematology

IPSOGEN, a leading provider of molecular diagnostic tests for the disease management of cancer patients, announced today that Dr. Cilloni will give an oral presentation of the results of a multi-center study performed within the...

Categorie: Leucémie

mardi 20 novembre 2007 Ipsogen launches the first quantitative JAK2 V617F mutation kit

IPSOGEN, a leading molecular diagnostic company based in Franceand Connecticut, announces the immediate availability of its new JAK2 MutaQuant™ Kit, a research tool intended for the accurate quantification of JAK2 V617F...

Categorie: Leucémie

lundi 17 septembre 2007 Ipsogen in-licenses NPM1 mutations’ technology from Xenomics

IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, today announced that it has signed a co-exclusive license agreement with XENOMICS (Pink Sheets: XNOM), a developer of next-generation medical DNA...

Categorie: Leucémie

lundi 10 septembre 2007 Ipsogen grants Labcorp a license for JAK2 testing in the US.

Marseille, France, September 10, 2007 - IPSOGEN, a leading provider of molecular diagnostic tests for the disease management of cancer patients, announced today the signing of an agreement with Laboratory Corporation of America®...

Categorie: Leucémie

lundi 10 septembre 2007 Ipsogen announced today the signing of an agreement with Laboratory Corporation of America® Holdings under which LabCorp will offer a JAK2 molecular diagnostic assay in the USA

IPSOGEN, a leading provider of molecular diagnostic tests for the disease management of cancer patients, announced today the signing of an agreement with Laboratory Corporation of America® Holdings (LabCorp®, NYSE: LH) under...

Categorie: Leucémie

mardi 14 août 2007 Ipsogen grants an exclusive licence to Warnex for JAK2 testing in CANADA

Marseille, France, August 14, 2007 – Ipsogen SAS. today announced the signature of an exclusive agreement with Warnex Inc. (TSX: WNX), a life sciences company devoted to protecting public health by providing laboratory services...

Categorie: Leucémie

vendredi 31 mars 2006 IPSOGEN licenses JAK2 mutation test to improve the diagnosis of blood-based disorders

Marseille, France, March 30, 2006

Read more

– IPSOGEN SAS, a molecular diagnostic company developing tests to improve disease management of cancer patients, announced today the signature of a license agreement with Institut...

Categorie: Leucémie

mercredi 09 février 2005 Ipsogen is formally accepted as a participant of the European LeukemiaNet.

Marseille, France, 9

“Ipsogen is privileged to have been accepted as a participant of this important European network. With Ipsogen’s focus and positioning as a leader in providing standardised validated IVD assays to clinical...

Categorie: Leucémie